Methylene blue’s drug interaction profile is more consequential than that of a typical supplement, because it is an FDA-approved pharmaceutical with a well-documented mechanism, potent monoamine oxidase inhibition, that interacts predictably and sometimes dangerously with a specific category of medications.
This article lays out the interaction categories that matter most, organized by mechanism and severity.
Key Takeaways
- Serotonergic medications (SSRIs, SNRIs, tricyclic antidepressants, tramadol, certain migraine drugs) carry the most serious interaction risk with methylene blue: serotonin syndrome.
- This interaction carries a boxed warning on the FDA-approved label, the agency’s most serious warning class, not a theoretical concern, and has resulted in documented adverse events, including in surgical and medical settings where methylene blue is used as a dye.
- Other MAOIs should not be combined with methylene blue, as the effects can compound.
- A complete medication and supplement review with a physician or pharmacist before starting methylene blue is the single most important safety step.
The Core Mechanism Behind the Risk
Methylene blue is a potent, reversible inhibitor of monoamine oxidase A, the enzyme responsible for breaking down serotonin in the body[1][2]. When methylene blue is combined with a medication that also raises serotonin activity, the two effects compound rather than simply add, creating a disproportionate risk of serotonin syndrome, a potentially fatal reaction involving agitation, hyperthermia, and neuromuscular instability.
Antidepressants: The Highest-Risk Category
SSRIs (such as sertraline, fluoxetine, escitalopram), SNRIs (such as venlafaxine, duloxetine), and older tricyclic antidepressants all carry serious interaction risk with methylene blue. This interaction is well enough documented that it has caused serious adverse events, including fatalities, in surgical patients who received methylene blue as a dye while on antidepressant therapy, which is part of why the FDA-approved label carries a boxed warning for this interaction rather than a routine precaution[1][3].
Other Serotonergic and MAOI Medications
Tramadol, a commonly prescribed opioid pain medication with serotonergic activity, carries the same risk category; the FDA-approved label directs prescribers to avoid combining methylene blue with opioids and dextromethorphan for this reason[1]. Triptans used for migraine treatment, other MAOIs, and certain antiemetics also fall into medications requiring caution or avoidance[1][4]. Combining methylene blue with another MAOI in particular can compound cardiovascular and neurological effects unpredictably.
Why a Full Review Matters More Than a Checklist
Because serotonergic activity shows up in medications people may not immediately associate with mood, certain pain medications, some anti-nausea drugs, migraine treatments, a general awareness of “antidepressants only” is not sufficient. A complete medication list, reviewed by a physician or pharmacist familiar with methylene blue’s specific interaction profile, is the most reliable way to catch a risk that a quick mental checklist might miss[5].
As an Amazon Associate and affiliate partner, this site earns from qualifying purchases linked in this article. This does not change the price you pay and does not influence the safety information below.
Frequently Asked Questions
What is the most dangerous drug interaction with methylene blue?
Combining methylene blue with serotonergic medications, particularly SSRIs, SNRIs, and tramadol, carries the most serious documented risk: serotonin syndrome, a potentially fatal reaction.
Can I take methylene blue if I’m on antidepressants?
This combination is not recommended without direct physician guidance and is generally avoided, given the well-documented serotonin syndrome risk.
Is tramadol dangerous with methylene blue?
Yes, tramadol has serotonergic activity and falls into the same high-risk interaction category as SSRIs and SNRIs for serotonin syndrome.
Why did methylene blue cause problems in surgical patients on antidepressants?
Documented cases, including fatalities, occurred when methylene blue was administered as a surgical dye to patients on antidepressant therapy, which is part of why the serotonin syndrome interaction carries a boxed warning on the FDA-approved label.
References
- U.S. Food and Drug Administration. PROVAYBLUE (methylene blue) injection — full prescribing information, Boxed Warning, Section 5.1 Serotonin Syndrome with Concomitant Use of Serotonergic Drugs and Opioids, and Section 7 DRUG INTERACTIONS. FDA prescribing information (2024). FDA label (PDF)
- Ramsay RR, Dunford C. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology (2007). PMID 17721552
- Zuschlag ZD, Warren MW. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics (2018). PMID 30104021
- Huang WH, Li MJ. Postoperative serotonin syndrome following administration of preoperative intrapulmonary methylene blue and intraoperative granisetron: a case report. The American Journal of Case Reports (2022). PMID 35619329
- McMillan E, Meepagala S. Prevalence of serotonergic drug use in patients exposed to perioperative methylene blue: a cross-sectional study. Cureus (2025). PMID 40271333
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.